Having successfully created AniCura in 2011, today part of Mars Petcare and representing one of the largest pet care and pet clinic chains in Europe, Fidelio decided to leverage its gained insights into the broader animal health industry. The journey started with investments in innovation-driven and entrepreneurial businesses within attractive sub-segments of animal health, with the ambition to combine these and establish global category leaders. At the time, many of these sub-segments were highly fragmented and served mainly by smaller, entrepreneurial businesses with limited capabilities to scale. On the other hand, they were also characterised by relatively high entry barriers and strong profitability, supported by scalable business models and IP/patent protection.

Vimian’s story begins in 2015 with Fidelio acquiring Artuvet Animal Health B.V., a provider of pet allergy diagnostics and treatment. Since then, Fidelio has, in collaboration with strong entrepreneurs and management teams of companies within Diagnostics(Indical Bioscience), Veterinary Services (VetFamily), and MedTech (Movora) targeting the companion and production animal health market, continued to build what today is known as Vimian – a global and diversified Group operating in four fast-growing animal health verticals.

Following the successful listing of Vimian on the Stockholm Stock Exchange in June 2021, with Fidelio retaining its role as an active majority owner, Vimian has continued to grow through an ambitious strategy across all businesses and verticals.